Core Insights - Investors in the Medical - Biomedical and Genetics sector should consider Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX) for potential value opportunities [1] Valuation Metrics - HRMY has a forward P/E ratio of 9.20, significantly lower than ARGX's forward P/E of 29.47 [5] - HRMY's PEG ratio is 0.34, while ARGX's PEG ratio is 0.54, indicating HRMY may offer better value relative to its expected earnings growth [5] - HRMY has a P/B ratio of 2.54 compared to ARGX's P/B of 8.18, further suggesting HRMY is undervalued [6] Zacks Rank and Earnings Outlook - HRMY holds a Zacks Rank of 1 (Strong Buy), indicating positive earnings estimate revisions, while ARGX has a Zacks Rank of 5 (Strong Sell) [3] - The stronger estimate revision activity for HRMY suggests a more favorable earnings outlook compared to ARGX [7] Value Grades - HRMY has a Value grade of A, while ARGX has a Value grade of D, reflecting HRMY's more attractive valuation metrics [6]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

Dianthus Therapeutics FY Conference Summary Company Overview - **Company**: Dianthus Therapeutics (NasdaqCM:DNTH) - **Focus**: Development of clinical-stage autoimmune therapeutics with a best-in-class pipeline targeting patient-friendly, infrequent subcutaneous self-administration [2][3] Key Products and Pipeline Clasibobart - **Description**: A potent classical pathway inhibitor with an eight-week half-life, targeting activated C1s - **Clinical Status**: Positive phase two results disclosed in September, with clinical proof of concept for classical pathway inhibition in Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [2][4] - **Administration**: 300 mg, 2 ml autoinjector dosed every two or four weeks [3][5] - **Market Potential**: Targeting over 150,000 patients in the U.S. for MG, CIDP, and Multifocal Motor Neuropathy (MMN) [5][6] - **Efficacy Data**: Impressive results with 300 mg every two weeks showing robust, statistically significant efficacy across five measures in MG [6][9] - **Phase 3 Trial**: Discussions with the FDA ongoing, aiming for a trial comparing placebo, Clasibobart every two weeks, and every four weeks [11][12] DNTH212 - **Description**: A bispecific fusion protein targeting BDCA2 and BAFF/APRIL pathways - **Clinical Status**: Currently in phase 1 trials, with plans to prioritize indications such as Systemic Lupus Erythematosus (SLE) and dermatomyositis [25][26] Market Opportunities Myasthenia Gravis (MG) - **Market Size**: Approximately 100,000 patients in the U.S. with ACHR positive MG [5] - **Competitive Advantage**: Clasibobart's mechanism may provide superior efficacy compared to existing C5 inhibitors by preventing pro-inflammatory toxins [10][11] Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - **Market Need**: High unmet need due to limitations of current treatments like IVIG and FcRns [13][14] - **Efficacy Signals**: Clasibobart showed better efficacy than IVIG in patients refractory to standard treatments [14][15] Multifocal Motor Neuropathy (MMN) - **Market Size**: Estimated 10,000-15,000 patients in the U.S. with a high potential for a blockbuster product due to lack of competition [21][33] - **Competitive Landscape**: Clasibobart is positioned against Empasibobart, with superior potency and a more convenient administration route [22][24] Financial Position - **Cash Reserves**: Approximately $514 million, providing a runway into 2028 [27] Additional Insights - **Trial Design**: Clasibobart's trial design allows for immediate switching from IVIG to Clasibobart, which may yield higher responder rates compared to traditional methods [19][20] - **Market Strategy**: Emphasis on the potential for Clasibobart to be the most convenient and patient-friendly biologic in MG and CIDP [12][13] - **Investor Considerations**: The company highlights the importance of looking at actions and trial designs rather than just statements when evaluating potential success [31][32] Conclusion Dianthus Therapeutics is positioned to make significant advancements in the treatment of autoimmune diseases with its innovative therapies, particularly Clasibobart, which shows promise in multiple indications and has a strong clinical and market strategy. The upcoming phase 3 trial and interim analyses are critical milestones to watch for potential investment opportunities.

Summary of Roivant Sciences FY Conference Call Company Overview - **Company**: Roivant Sciences (NasdaqGS:ROIV) - **Event**: FY Conference Call on January 12, 2026 - **Speaker**: CEO Matt Gline Key Points Company Positioning and Strategy - Roivant is entering a new era with a significantly simplified business model focused on a smaller subset of products, emphasizing clinical execution and pipeline potential [3][4] - The company aims to shape its own destiny with a high priority on delivering results from its clinical programs [3] Financial Strength - Roivant reported a cash balance of **$4.4 billion**, positioning it well for future growth without the need for additional fundraising [5][9] - The company has a strong track record with **12 positive phase III studies** and **8 FDA approvals**, indicating robust past performance and a solid pipeline [9] Clinical Development Highlights - **Brepocitinib**: Positive data for dermatomyositis (DM) with plans to file an NDA by early 2026, marking it as the first novel oral therapeutic for DM [4][5] - **IMVT-1402**: Progressing in pivotal studies for Graves' disease, with expectations for significant disease-modifying benefits [4] - Upcoming data releases include registrational programs for brepocitinib in non-infectious uveitis (NIU) and phase IIb data for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) [6][7] Market Opportunities - The company sees a potential **$15 billion-plus portfolio** across various indications, with significant opportunities in DM, NIU, and Graves' disease [19][70] - Brepocitinib is expected to capture market share from existing therapies, particularly for patients currently on high-dose steroids or IVIG [41][42] Competitive Landscape - Roivant is positioned to be among the first non-prostacyclin novel mechanisms in PH-ILD, competing against established treatments [6][57] - The company is optimistic about the potential for brepocitinib to outperform existing treatments in DM, especially given the enthusiasm from physicians [41][46] Legal and Regulatory Environment - Ongoing litigation with Moderna regarding lipid nanoparticle technology, with a jury trial scheduled for March 2026 [5][60] - The outcome of this case may have implications for other ongoing litigations and the company's overall strategy [62] Future Outlook - Roivant anticipates a transformative next 36 months with multiple commercial launches and pivotal study readouts [11][19] - The company is focused on executing its clinical programs and expanding its pipeline to drive future value [19][29] Unique Business Model - Roivant's model combines talent from various backgrounds, emphasizing creative clinical development and a focus on delivering value to patients [10][30] - The company aims to differentiate itself by maintaining high standards for partnerships and transactions, driven by a focus on profitability [36] Conclusion - Roivant Sciences is positioned for significant growth with a strong financial foundation, a focused pipeline, and a commitment to innovative clinical development. The upcoming years are expected to be pivotal for the company as it seeks to capitalize on its opportunities in the biotech space [19][70]

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3] - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, evaluating its potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines [3] Upcoming Event - Tim Van Hauwermeiren, the Chief Executive Officer of argenx, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 8:15 a.m. PT [1] - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2]

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Keros Therapeutics, Inc. (KROS) and argenex SE (ARGX) for potential value opportunities, with KROS appearing to offer better value at this time [1]. Valuation Metrics - KROS has a forward P/E ratio of 9.16, significantly lower than ARGX's forward P/E of 47.56, indicating KROS may be undervalued [5]. - The PEG ratio for KROS is 0.25, while ARGX has a PEG ratio of 0.87, suggesting KROS has a more favorable earnings growth outlook relative to its price [5]. - KROS's P/B ratio is 0.89, compared to ARGX's P/B of 8.41, further indicating KROS's stock may be undervalued relative to its book value [6]. Earnings Estimate Revisions - KROS has a Zacks Rank of 1 (Strong Buy), reflecting positive earnings estimate revisions, while ARGX has a Zacks Rank of 3 (Hold), indicating less favorable earnings outlook [3][7]. - The stronger estimate revision activity for KROS suggests a more optimistic earnings outlook compared to ARGX, making KROS a more attractive option for value investors [7].

Core Viewpoint - Argenx SE (ARGX) shares declined following a downgrade by Baird due to valuation concerns after a setback in a late-stage trial for its leading therapy, Vyvgart [2] Company Summary - Argenx SE experienced a drop in stock price after announcing issues with its best-selling therapy, Vyvgart, which has raised concerns among analysts regarding the company's valuation [2]

Core Insights - The analysis focuses on argenx SE's lead product, VYVGART HYTRULO, and a recent safety event related to its use in CIDP patients, indicating that the transition from IVIG to VYVGART HYTRULO may be the primary concern rather than the drug itself [1] Group 1 - The safety event discussed pertains to the transition process for CIDP patients moving from IVIG to VYVGART HYTRULO [1]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 200 points [1] - Argenx SE shares fell 6% to $825.00 in pre-market trading after discontinuing Phase 3 studies of efgartigimod SC in thyroid eye disease [1] Group 2 - TryHard Holdings Ltd shares tumbled 15.2% to $13.16 in pre-market trading after a previous jump of 58% [2] - Site Centers Corp declined 13.4% to $6.33 in pre-market trading [2] - Exicure Inc dipped 8.7% to $5.80 in pre-market trading after gaining 5% on Friday [2] - Celldex Therapeutics Inc declined 8.4% to $25.19 in pre-market trading [2] - CapsoVision Inc fell 6.4% to $12.03 in pre-market trading after a decline of around 11% on Friday [2] - Zillow Group Inc fell 5.6% to $70.50 in pre-market trading [2] - BeOne Medicines AG declined 4.9% to $303.50 in pre-market trading [2] - ServiceNow Inc fell 4.7% to $824.50 in pre-market trading after a downgrade to Underweight by KeyBanc [2] - WaterBridge Infrastructure LLC fell 4.4% to $20.05 in pre-market trading [2] - Pharming Group N V declined 4.2% to $17.23 in pre-market trading [2]

Market Movements - US stock index futures are all up, with Dow futures rising by 0.47%, S&P 500 futures up by 0.50%, and Nasdaq futures also increasing by 0.50% [1] - European indices are also showing positive movements, with Germany's DAX up by 0.44%, UK's FTSE 100 up by 0.94%, France's CAC40 up by 1.13%, and the Euro Stoxx 50 up by 0.74% [1] Commodity Prices - WTI crude oil has decreased by 0.42%, trading at $57.00 per barrel, while Brent crude oil has fallen by 0.41%, priced at $60.87 per barrel [2] Economic News - The market is focused on the potential candidates to succeed Jerome Powell as the next Federal Reserve Chair, with President Trump suggesting Kevin Hassett or Kevin Warsh [3] - Key economic data, including the November employment report and CPI data, are set to be released this week, following a recent 25 basis point rate cut by the Fed [3][4] - The bond market is engaged in intense discussions regarding the Fed's future rate cuts, with expectations of two rate cuts next year despite persistent inflation [4] Company News - iRobot has filed for Chapter 11 bankruptcy protection, indicating that existing common stockholders will not receive any equity in the restructured company [6][7] - STMicroelectronics is expected to deliver over 5 billion Starlink chips in the next two years, reflecting the growing demand in the commercial space sector [7] - Sanofi's multiple sclerosis drug tolebrutinib faces delays in FDA approval and has failed in a late-stage trial, potentially threatening its projected $1.7 billion annual sales peak [8] - Argenx has terminated its trial for a thyroid eye disease drug based on recommendations from an independent data monitoring committee, impacting its treatment goals [8] - Rocket Lab has successfully executed its first dedicated launch mission for JAXA, marking a significant milestone for the company in the commercial space sector [9]